Stockscreener 앱 받기
32.81
2.69%
0.86
시간 외 거래:
32.81
전일 마감가:
$31.95
열려 있는:
$32.5
하루 거래량:
547.64K
Relative Volume:
0.70
시가총액:
$1.60B
수익:
$109.79M
순이익/손실:
$-153.49M
주가수익비율:
-10.22
EPS:
-3.2098
순현금흐름:
$-172.59M
1주 성능:
+17.18%
1개월 성능:
+14.00%
6개월 성능:
+45.05%
1년 성능:
+147.81%
1일 변동 폭
$32.17
$33.40
1주일 범위
$27.82
$33.40
52주 변동 폭
$12.73
$33.40
Urogen Pharma Ltd Stock (URGN) Company Profile
명칭
Urogen Pharma Ltd
전화
972 9 770 7601
주소
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
32.81 | 1.50B | 109.79M | -153.49M | -172.59M | -3.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Jefferies | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-06-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-19 | 재개 | Ladenburg Thalmann | Buy |
| 2024-08-22 | 개시 | Guggenheim | Buy |
| 2023-02-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-27 | 개시 | Berenberg | Buy |
| 2020-04-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-13 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-09 | 개시 | National Securities | Neutral |
| 2019-05-30 | 개시 | JP Morgan | Neutral |
| 2019-05-29 | 개시 | Goldman | Neutral |
| 2019-01-29 | 개시 | H.C. Wainwright | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-04-04 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | 개시 | Ladenburg Thalmann | Buy |
| 2017-11-15 | 재확인 | Oppenheimer | Outperform |
| 2017-11-15 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
모두보기
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? - The Motley Fool
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? - The Motley Fool
URGN Stock Price, Quote & Chart - ChartMill
UroGen settles with Teva over Jelmyto patent dispute - MSN
UroGen Pharma CMO Mark Schoenberg sells $142,560 in shares By Investing.com - Investing.com Australia
UroGen Pharma Ltd stock (IL0011408896): Focus on urology pipeline after recent clinical updates - AD HOC NEWS
UroGen Pharma CMO Mark Schoenberg sells $142,560 in shares - Investing.com UK
UroGen Pharma (URGN) Gains Ground: Analyzing the Uptrend Above $27Initial Balance - newsline.com
Insider Sale: Chief Medical Officer of $URGN Sells 5,222 Shares - Quiver Quantitative
UroGen Pharma (URGN) CMO nets shares as RSUs vest and 5,222 sold for tax - Stock Titan
Mark Schoeberg sells 10,000 shares of UroGen (URGN) reported in Form 144 - Stock Titan
How Resolving Jelmyto Patent Litigation And Setting 2030 Generic Entry At UroGen Pharma (URGN) Has Changed Its Investment Story - simplywall.st
UroGen Pharma (URGN) Gains Ground: Positive Momentum Breaks Key ThresholdVolume Breakout Ideas - newsline.com
UROGEN PHARMA LTD (NASDAQ:URGN) Flawlessly Passes Minervini Trend Template with Accelerating Growth - ChartMill
Will UroGen’s Jelmyto Generic Deal with Teva Redefine UroGen Pharma's (URGN) Narrative? - Yahoo Finance
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
Assessing UroGen Pharma (URGN) Valuation After Jelmyto Patent Settlement With Teva - simplywall.st
(URGN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
UroGen Pharma Ltd stock (IL0011408896): Nasdaq inducement grants and valuation metrics in focus - AD HOC NEWS
UroGen Pharma, Teva End Patent Dispute Over Urinary Cancer Drug - Bloomberg Law News
URGN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
UroGen Pharma stock reaffirmed at Buy by H.C. Wainwright on Teva settlement - Investing.com South Africa
Oppenheimer reiterates Outperform on UroGen Pharma stock after Teva settlement - Investing.com Australia
UroGen Pharma (URGN) Settles Patent Dispute with Teva Pharmaceuticals (TEVA) - GuruFocus
[8-K] UroGen Pharma Ltd. Reports Material Event - Stock Titan
UroGen Announces Agreement Resolving Patent Litigation - GlobeNewswire
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
What's Driving Investor Interest in UroGen Pharma (URGN) Ahead of Goldman Sachs - Kavout
Hear UroGen’s Goldman Sachs healthcare chat online with 90-day replay - Stock Titan
UroGen Pharma Ltd stock (IL0011408896): recent gains put valuation in focus - AD HOC NEWS
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge - AOL.com
[ARS] UroGen Pharma Ltd. SEC Filing - Stock Titan
UroGen Pharma (URGN) director converts 2,000 RSUs into ordinary shares, holds 6,000 - stocktitan.net
Liquidity Mapping Around (URGN) Price Events - Stock Traders Daily
URGN: ZUSDURI adoption accelerates with robust Q1 growth and pipeline advances set for 2024-2027 - TradingView
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $45 - 富途牛牛
How UGN-103’s Phase 3 Data and NDA Timeline Could Reshape UroGen Pharma (URGN) Investors’ Outlook - simplywall.st
Urogen Pharma Ltd (URGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):